vimarsana.com
Home
Live Updates
Ferring Pharmaceuticals' 1st in Class C.diff Treatment, Reby
Ferring Pharmaceuticals' 1st in Class C.diff Treatment, Reby
Ferring Pharmaceuticals' 1st in Class C.diff Treatment, Rebyota, Experiences a Positive Early Launch Ahead of Potential Competition, According to Spherix Global Insights
/PRNewswire/ -- When the FDA approved Rebyota, a new class of Clostridioides Difficile (C.diff) treatment, Ferring Pharmaceuticals ushered in the first...
Related Keywords
Scott Upham ,
Finch Pharmaceuticals ,
Linkedin ,
Twitter ,
Corporate Communications ,
Ferring Pharmaceuticals ,
Dynamix ,
Spherix Network ,
Challenge First ,
Market Ferring ,
Clostridioides Difficile ,
Fecal Microbiota Transplant ,
Spherix Global Insights Market Dynamix ,
Vedanta Bioscience ,
Launch Dynamix ,
Market Dynamix ,
Global Insights ,
Spherix Global Insights ,
Franchise Leader ,
Spherix Global Insight ,